The impact of lemborexant on daytime functioning in adults with insomnia скачать в хорошем качестве

The impact of lemborexant on daytime functioning in adults with insomnia

Margaret Moline, PhD, Eisai Inc., Nutley, NJ, discusses an analysis of the SUNRISE 2 trial (NCT02952820), exploring the effect of lemborexant on daytime functioning in adults with insomnia. Dr Moline highlights that while objective sleep studies may show improvements in sleep duration, patients need to experience subjective improvements in their sleep quality to feel better. The Lemborexant Clinical Development Program used various methods to assess daytime functioning, including the Insomnia Severity Index and Fatigue Severity Scale, and found that patients experienced significant improvements in insomnia severity, daytime functioning, and fatigue over six months of treatment. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.